



**2008 European Immunoassay
Excellence in Technology Award**



"We accelerate growth"

2008 European Immunoassay Excellence in Technology Award

Award Description

Frost & Sullivan's Excellence in Technology Award is bestowed upon a company that has pioneered the development and introduction of an innovative technology into the market; a technology that has either impacted or has the potential to impact several market sectors. This award recognizes a company's successful technology development that is expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. It also recognizes the company's overall technical excellence and its commitment toward technology innovation.

Research Methodology

To choose the award recipient, Frost & Sullivan's analyst team tracks technology innovation in key hi-tech markets. The selection process includes primary participant interviews and extensive primary and secondary research via the bottom-up approach. The analyst team shortlists candidates on the basis of a set of qualitative and quantitative measurements. The analysts also consider the pace of technology innovation, and the potential relevance or significance of the technology to the overall industry. The ultimate award recipient is chosen after a thorough evaluation of this research.

Measurement Criteria

In addition to the methodology described above, there are specific criteria used to determine the final rankings. The recipient of this award has excelled based on one or more of the following criteria:

- Number of new technologies developed or introduced
- Significance of a technology/ technologies in the industry
- Competitive advantage of technology/technologies vis-à-vis competing technologies
- Ease of adoption of new technology/technologies
- Potential of technology/technologies to become an industry standard
- General impact of technology in terms of shifting R&D focus



The “2008 European Immunoassay Excellence in Technology Award” is presented to Chimera Biotec GmbH for its technology know-how and expertise in the area of immuno-PCR, an emerging area in immunoassay market. This award is in recognition of the company’s ability to successfully deliver its services based on its proprietary Imperacer® protein detection technology to the diagnostic and pharmaceutical industry.

Headquartered in Dortmund, Chimera Biotec GmbH is a service provider for the life sciences community, providing tailor-made solutions and products utilizing its proprietary technology. Its vast knowledge in this area along with technical expertise places them in a better position in the European region.

The need for a new technology with good sensitivity involving immunological technique to detect protein has ever since been an unmet need in the immunoassay market. The huge success of ELISA’s has slightly hindered the development of competing technologies simply because of its cost effectiveness and easy performance. However, the current need to develop novel protein biomarker for disease detection is demanding a better technology with higher sensitivity and less matrix interference. This current demand has encouraged the need to develop immuno-PCR techniques which were first introduced way back in 1992.

Imperacer® protein detection technology – Highly robust I-PCR technology

Imperacer is a combination of antibody-DNA conjugates and PCR technique aimed at improving the sensitivity of traditional immunoassays. With a 1000-fold increase in sensitivity compared to traditional immunoassays and dynamic range up to six orders of magnitude, this technology is currently applicable in areas like drug development, Alzheimer disease diagnosis, anti-doping testing and vaccine development

Easy Performance Targets Better Adoption

The sharp decline in the skilled laboratory workforce is one of the major challenges faced by the diagnostics industry. A novel technology which requires proper training of personnel to perform the tests is a hitch in the adoption of new technologies in the market. But Imperacer was developed and refined bearing this in mind. Imperacer assays have a simple protocol which is a key strength for easy adoption in the market. Together, there is no need for laboratories to invest in equipments to perform these assays as a PCR instrument which is commonly used in laboratories will serve the purpose.

Raising Importance Proves Future Potential

Though immuno-PCR technology has been available in the market for more than 5 years, there is a growing focus to develop assays based on this concept. Today, in the market place a number of companies are seen pursuing active research in this area. A US based company has advanced to the stage of approval and commercial launch of first immuno-PCR assay for clinical use. This raising importance in the market for is likely to transform immunological testing in the laboratories.

Together, innovations are being made in this technology such as the use of magnetic nanoparticles which is called as Magneto Immuno-PCR (M-IPCR) which are 1000-fold more sensitive compared to ELISA based tests.

Conclusion

The ability to develop the concept of immuno-PCR into a novel technology which can provide easy to perform and robust assays which has the potential to cater the future detection needs in the market commends appreciation in the market. Chimera Biotec's expertise, along with its ongoing research and commitment in immuno-PCR research is recognized by Frost & Sullivan and these abovementioned factors make it the deserving recipient of the "2008 European Immunoassay Excellence in Technology Award."

About Best Practices

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.



About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit <http://www.frost.com>.

Catherine Brassell
Frost & Sullivan
DDI: +44.207.915.7867
Email: catherine.brassell@frost.com
www.frost.com